高通量血液透析对糖尿病肾病透析患者氧化应激及微炎症状态的影响被引量：69

下载PDF

导出

摘要目的观察高通量血液透析(HFHD)对糖尿病肾病血液透析患者氧化应激及微炎症状态的影响。方法选择透析时间超过6个月的糖尿病肾病血液透析患者50例,分为HFHD组和低通量血液透析(LFHD)组,每组各25例。检测两组治疗前及治疗6个月后血清高敏C反应蛋白(hs-CRP)、IL-6、肿瘤坏死因子α(TNF-α)、过氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)变化。结果与治疗前相比LFHD组患者血IL-6、TNF-α、hs-CRP、MDA水平均显著升高(P<0.05),SOD、GSH-Px显著降低(P<0.05);HFHD组与治疗前相比,IL-6、TNF-α、hs-CRP、MDA水平均显著降低(P<0.05),SOD、GSH-Px显著升高(P<0.05);两组治疗后组间比较差异有统计学意义(P<0.05)。结论糖尿病肾病血液透析患者体内普遍存在氧化应激及微炎症状态,长期LFHD可加重体内氧化应激水平及炎性反应,HFHD可缓解氧化应激及炎性反应。

作者易晔卢远航冀倩倩

机构地区湖北省中山医院血液净化中心

出处《重庆医学》 CAS 北大核心 2015年第19期2667-2669,共3页 Chongqing medicine

关键词高通量血液透析糖尿病肾病氧化性应激微炎症

分类号 R459.5 [医药卫生—治疗学]

引文网络
相关文献

参考文献12

1Locatelli F,Martin-Malo A,Hannedouche T,et a1. Effect of membrane permeability on survival of hemodialvsis patients[J].J Am Soc Nephrol,2009,20(3):645-654.
2Krasniak A, Drozdz M, Pasowicz M, et al. Influence of rnicroinflammation and oxidative stress on atherosclerosis progression and calcifications in cardiovascular system of hernodialyzed patients during two years follow-up [J]. Przegl Lek, 2007,64(3) : 140-147.
3Meuwese CL,Stenvinkel P,Dekker FW,et al. Monitoring of inflammation in patients on dialysis: forewarned is forearmed[J]. Nat Rev Nephrol , 2011,7(3) : 166-176.
4Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes[J]. Inflamm Allergy Drug Targets, 2009, 8 (5) : 369-382.
5Witko Sarsat V,Gausson Vv Nguyen AT,et al. AOPP induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for nacetylcysteine treatment in dialysis patients[J]. Kidney Int , 2003,64(1) : 82-91.
6Wen JP, LiangYB, Wang FH, et al. C-reactive protein. Gamma-glutamylrransferase and type2 diabetes in a Chinese population[J]. Clinica Chimica Acta, 2010, 411( 3) : 198-203.
7Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy[J]. Semin Dial, 2009(22): 636-643.
8Macias Nunez JF ,Ghais Z,Bustamante J .et al. Evaluation of oxidant-antioxidant balance in patients on maintenance hemodialysis: a comparative study of dialyzers membranes [J]. Nephron Clin Pract,2010,114(1) :c67-73.
9Davenport A. The role of dialyzer membrane flux in Bioincompatibility[J]. Hemodial Int , 2008,12 (Suppl 2): 29- 33.
10刘丽艳,翟增云,许冬梅.维生素E对维持性血液透析患者静脉补铁诱导的氧化应激及脂代谢紊乱的影响[J].国际移植与血液净化杂志,2009,7(4):38-41. 被引量：5

二级参考文献20

1YoshitioM, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality [J]. J Am Soc Nephrol, 2006, 17: 3510-3519.
2Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: Classification, concentration, and interindividual variability[J]. Kidney Int, 2003, 63:1934- 1943.
3Vanholder R, Meert N, Schepers E, et al. Uremic toxins: Do we know enough to explain uremia[J]. Blood Purif, 2008, 26: 77-81.
4Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identi fled as beta 2 microglobulin[J]. Biochem Biophys Res Commun, 1985, 129:701 -706.
5Bember LM, Jaber BL. Dialysis- ReLated Amyloidosis: Late Finding or Hidden Epidemic[J]. Seminars in Dialysis, 2006, 19:105-109.
6Cheung AK, Rocco MV, gan G, et al. Serum β2- microglobulin levels predict mortality in dialysis patients: results of the HEMO study[J]. J Am Soc Nephrol, 2006, 17:546- 555.
7Okuno S, Ishimura E, Rohno K, et al. Serum β2-microglobulin level is a significant predictor of mortality in mainte nance haemodialysis patients[J]. Nephrol Diat Transplant, 2009, 24: 571-577.
8Nakai S, Iseki K, Tabei K, et al. Outcomes of hermdiafiltration based on Japanese dialysis patient registry[J]. Am J Kidney Disease, 2001, 38: S212-216.
9Furuya R, Kumaqai B, Takahashi M, et al. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients[J]. Blood Purif, 2005,23:311- 316.
10Masakane I. Review: Clinical usefulness of ultrapure diaiysate -recent evidence and perspectives[J]. Ther Apher Dial, 2006, 10: 348-354.